C21 · Pharmaceuticals · Global
KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer
Global: 79 in 1 Jan 2023 to 27 Sep 2026.
- 79 Latest · Global · 1 Jan 2023 to 27 Sep 2026
- Irregular Release cadence
- 1 Record · 1 region · 2023–2026
Verified 27 Sep 2026 · 1 publisher
The figure
One published observation so far. A chart follows as soon as a second period is published.
KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer
Global, 1 Jan 2023 to 27 Sep 2026
Every record
1 record · 1 region · 2023–2026. Each period links to its record: the value, the quote it was read from, and the document.
| Period | Value | Source | Type |
|---|---|---|---|
| Global 1 record | |||
| 1 Jan 2023 to 27 Sep 2026 | 79 | ClinicalTrials.gov · 27 Sep 2026 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: ClinicalTrials.gov. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (ClinicalTrials.gov); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Count of interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) whose conditions include pancreatic cancer, started from 2023-01-01 to 2026-09-27.
- Measure
- One slice of Clinical trial starts ( basis: clinicaltrials gov registry, counting rule: by start date, form: count, segment: kras pdac ) . Total number of clinical trials initiated during a given period. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its quote before publication. See the methodology and the corrections process.
Sources · 1 document
Other slices of clinical trial starts
- Alzheimer's disease drug trial starts 21 clinicaltrials gov registry · by start date · alz
- Antibody-drug conjugate trial starts 21 clinicaltrials gov registry · by start date · adc
- Autoimmune cell therapy and T-cell engager trial starts 21 clinicaltrials gov registry · by start date · autoimmune
- Cardiometabolic RNA and next-generation lipid drug trial starts 21 clinicaltrials gov registry · by start date · rnacv
- GLP-1, incretin multi-agonist and amylin trial starts 21 clinicaltrials gov registry · by start date · glp1
- Gene editing trial starts 21 clinicaltrials gov registry · by start date · gene
- Inflammatory bowel disease drug trial starts 21 clinicaltrials gov registry · by start date · ibd
- KRAS and RAS inhibitor trial starts 21 clinicaltrials gov registry · by start date · kras
- Oncology bispecific antibody trial starts 21 clinicaltrials gov registry · by start date · bsab
- Radioligand therapy trial starts 21 clinicaltrials gov registry · by start date · rlt
- Phase I small molecule clinical trial share 6 phase 1 small molecule
- Large company small molecule share of Phase I clinical trial starts 4 large company phase 1 small molecule
Frequently asked questions
What is the latest KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer?
Global: 79 in 1 Jan 2023 to 27 Sep 2026.
Where does this data come from?
From 1 document published by ClinicalTrials.gov. Every figure on this page links to its record, which quotes the sentence or table row the number was read from.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer [Data set]. Retrieved September 29, 2026, from https://statorigin.org/indicators/ctgov-kras-trial-starts-pdac
"KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer." StatOrigin, 2026, https://statorigin.org/indicators/ctgov-kras-trial-starts-pdac. Accessed 29 Sep. 2026.
StatOrigin. "KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/indicators/ctgov-kras-trial-starts-pdac.
@misc{statorigin_ctgov_kras_trial_starts_pdac_2026, title = {KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/ctgov-kras-trial-starts-pdac}, note = {Data set. Accessed 2026-09-29} }